These Analysts Cut Their Forecasts On Monday.com Following Q2 Results

Monday.com (MNDY) reported robust Q2 revenue of $299 million, a 27% year-over-year increase, fueled by strong enterprise demand and customer growth, with its monday CRM product achieving $100 million in ARR. The company also provided optimistic Q3 and full-year revenue guidance. Despite this strong operational performance and CEO emphasis on AI innovation, MNDY shares declined 1.1% post-earnings, as numerous analysts, while largely maintaining positive ratings, significantly reduced their price targets, indicating a recalibration of valuation expectations despite solid underlying fundamentals.

Analysis

Monday.com (MNDY) demonstrated strong operational performance in its second-quarter report, with revenue growing 27% year-over-year to $299 million, driven by robust demand from enterprise clients. The company highlighted significant customer momentum, achieving a record number of new clients generating over $100,000 in annual recurring revenue (ARR) and seeing its monday CRM product reach the $100 million ARR milestone. Forward guidance remains solid, projecting 24% to 25% revenue growth for the third quarter. However, a significant disconnect exists between these strong fundamentals and market sentiment. The stock declined 1.1% following the announcement, and a broad cohort of analysts, while largely maintaining 'Buy' or 'Overweight' ratings, implemented substantial cuts to their price targets. For example, B of A Securities reduced its target from $340 to $240 and UBS slashed its from $310 to $215. This widespread recalibration, even amid a rating upgrade from Morgan Stanley, suggests that while analysts still believe in the company's long-term strategy, including its AI initiatives, they are adjusting valuation multiples downwards, possibly due to broader market concerns or a tempered view on the sustainability of high growth rates.

Key Decisions for Investors

• Investors should recognize the strong underlying fundamentals, including 27% revenue growth and positive forward guidance, which confirm the company's operational execution.
• The broad-based, significant price target cuts from at least nine separate analyst firms, despite maintained buy-equivalent ratings, must be viewed as a critical signal of valuation compression and a key risk factor to monitor.
• Consider whether the 1.1% stock price decline and reduced analyst targets present a buying opportunity based on strong fundamentals, or if the analyst consensus signals a need for caution until the valuation disconnect resolves.